These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32233506)

  • 1. Targeted Amino Acid Substitution Overcomes Scale-Up Challenges with the Human C5a-Derived Decapeptide Immunostimulant EP67.
    Alshammari AM; Smith DD; Parriott J; Stewart JP; Curran SM; McCulloh RJ; Barry PA; Iyer SS; Palermo N; Phillips JA; Dong Y; Ronning DR; Vennerstrom JL; Sanderson SD; Vetro JA
    ACS Infect Dis; 2020 May; 6(5):1169-1181. PubMed ID: 32233506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.
    Karuturi BV; Tallapaka SB; Phillips JA; Sanderson SD; Vetro JA
    Clin Immunol; 2015 Dec; 161(2):251-9. PubMed ID: 26111481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists.
    Li XX; Clark RJ; Woodruff TM
    Int Immunopharmacol; 2021 Nov; 100():108074. PubMed ID: 34454293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.
    Tallapaka SB; Karuturi BVK; Yeapuri P; Curran SM; Sonawane YA; Phillips JA; David Smith D; Sanderson SD; Vetro JA
    Int J Pharm; 2019 Jun; 565():242-257. PubMed ID: 31077762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.
    Morgan EL; Morgan BN; Stein EA; Vitrs EL; Thoman ML; Sanderson SD; Phillips JA
    Vaccine; 2009 Dec; 28(2):463-9. PubMed ID: 19836478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
    Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
    Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection.
    Hung CY; Hurtgen BJ; Bellecourt M; Sanderson SD; Morgan EL; Cole GT
    Vaccine; 2012 Jun; 30(31):4681-90. PubMed ID: 22575167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.
    Sanderson SD; Thoman ML; Kis K; Virts EL; Herrera EB; Widmann S; Sepulveda H; Phillips JA
    PLoS One; 2012; 7(7):e40303. PubMed ID: 22792270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone.
    Phillips JA; Morgan EL; Dong Y; Cole GT; McMahan C; Hung CY; Sanderson SD
    Bioconjug Chem; 2009 Oct; 20(10):1950-7. PubMed ID: 19788175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface Modification of Biodegradable Microparticles with the Novel Host-Derived Immunostimulant CPDI-02 Significantly Increases Short-Term and Long-Term Mucosal and Systemic Antibodies against Encapsulated Protein Antigen in Young Naïve Mice after Respiratory Immunization.
    Parriott JE; Stewart JP; Smith DD; Curran SM; Bauer CD; Wyatt TA; Phillips JA; Lyden E; Thiele GM; Vetro JA
    Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel adjuvant for vaccine development in the aged.
    Morgan EL; Thoman ML; Sanderson SD; Phillips JA
    Vaccine; 2010 Dec; 28(52):8275-9. PubMed ID: 20965299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide.
    Sheen TR; Cavaco CK; Ebrahimi CM; Thoman ML; Sanderson SD; Morgan EL; Doran KS
    Vaccine; 2011 Dec; 30(1):9-13. PubMed ID: 22044742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement C5a Induces Pro-inflammatory Microvesicle Shedding in Severely Injured Patients.
    Karasu E; Demmelmaier J; Kellermann S; Holzmann K; Köhl J; Schmidt CQ; Kalbitz M; Gebhard F; Huber-Lang MS; Halbgebauer R
    Front Immunol; 2020; 11():1789. PubMed ID: 32983087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cells.
    Hegde GV; Meyers-Clark E; Joshi SS; Sanderson SD
    Int Immunopharmacol; 2008 Jun; 8(6):819-27. PubMed ID: 18442785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic activity of synthetic analogues of C5a anaphylatoxin.
    Ember JA; Sanderson SD; Taylor SM; Kawahara M; Hugli TE
    J Immunol; 1992 May; 148(10):3165-73. PubMed ID: 1578141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection.
    Kacani L; Bánki Z; Zwirner J; Schennach H; Bajtay Z; Erdei A; Stoiber H; Dierich MP
    J Immunol; 2001 Mar; 166(5):3410-5. PubMed ID: 11207298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decapeptide agonists of human C5a: the relationship between conformation and neutrophil response.
    Sanderson SD; Kirnarsky L; Sherman SA; Vogen SM; Prakash O; Ember JA; Finch AM; Taylor SM
    J Med Chem; 1995 Sep; 38(18):3669-75. PubMed ID: 7658455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1.
    Pandey S; Li XX; Srivastava A; Baidya M; Kumari P; Dwivedi H; Chaturvedi M; Ghosh E; Woodruff TM; Shukla AK
    J Biol Chem; 2019 Jun; 294(24):9416-9429. PubMed ID: 31036565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cleavage of the human C5A receptor by proteinases derived from Porphyromonas gingivalis: cleavage of leukocyte C5a receptor.
    Jagels MA; Ember JA; Travis J; Potempa J; Pike R; Hugli TE
    Adv Exp Med Biol; 1996; 389():155-64. PubMed ID: 8861006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism.
    Otto M; Hawlisch H; Monk PN; Müller M; Klos A; Karp CL; Köhl J
    J Biol Chem; 2004 Jan; 279(1):142-51. PubMed ID: 14570896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.